← Eichor
Study identifier: NCT06926491 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia(AOBA Study)

Condition: Achondroplasia  ·  Sponsor: Kyowa Kirin Co., Ltd.

PhasePhase 3
Planned participants6
Who can joinAll sexes, 3 Years to 18 Years
Healthy volunteersNo

About this study

This trial will evaluate the efficacy of KK8398 on annualized height velocity after 52 weeks of repeated administration of KK8398 to patients with achondroplasia

This description comes directly from the study's public registry record.

Talk to the study team

Kyowa Kirin Co., Ltd.  ·  +81-3-5205-7200  ·  clinical.info.jp@kyowakirin.com

Always discuss trial participation with your own doctor first.

Locations (9)

Aichi Children's Health and Medical CenterŌbu, Aichi-ken, JapanRecruiting
Osaka University HospitalSuita, Osaka, JapanRecruiting
Osaka Women's and Children's HospitalWaizumi, Osaka, JapanRecruiting
Tokyo Metropolitan Children's Medical CenterFuchū, Tokyo, JapanRecruiting
Tottori University HospitalYonago, Tottori, JapanRecruiting
Niigata University Medical and Dental HospitalNiigata, JapanRecruiting
Okayama University HospitalOkayama, JapanRecruiting
ISEIKAI International General HospitalOsaka, JapanRecruiting
Osaka City General HospitalOsaka, JapanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06926491